Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Iteos Therapeutics Inc (ITOS)

Iteos Therapeutics Inc (ITOS)
3.53 x 10 7.56 x 2
Post-market by (Cboe BZX)
5.63 -0.34 (-5.70%) 04/01/25 [NASDAQ]
3.53 x 10 7.56 x 2
Post-market 5.64 +0.01 (+0.18%) 19:48 ET
Quote Overview for Tue, Apr 1st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
5.62
Day High
5.97
Open 5.97
Previous Close 5.97 5.97
Volume 291,200 291,200
Avg Vol 365,665 365,665
Stochastic %K 2.88% 2.88%
Weighted Alpha -61.32 -61.32
5-Day Change -0.88 (-13.58%) -0.88 (-13.58%)
52-Week Range 5.62 - 18.75 5.62 - 18.75
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 228,018
  • Shares Outstanding, K 38,194
  • Annual Sales, $ 35,000 K
  • Annual Income, $ -134,410 K
  • EBIT $ -150 M
  • EBITDA $ -161 M
  • 60-Month Beta 1.38
  • Price/Sales 6.90
  • Price/Cash Flow N/A
  • Price/Book 0.39

Options Overview Details

View History
  • Implied Volatility 79.69% ( +18.51%)
  • Historical Volatility 50.43%
  • IV Percentile 28%
  • IV Rank 25.38%
  • IV High 255.25% on 01/14/25
  • IV Low 19.98% on 10/22/24
  • Put/Call Vol Ratio 0.17
  • Today's Volume 48
  • Volume Avg (30-Day) 61
  • Put/Call OI Ratio 2.58
  • Today's Open Interest 10,898
  • Open Int (30-Day) 17,271

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.91
  • Number of Estimates 3
  • High Estimate -0.66
  • Low Estimate -1.39
  • Prior Year -1.07
  • Growth Rate Est. (year over year) +14.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.62 +0.18%
on 04/01/25
Period Open: 7.26
7.65 -26.41%
on 03/13/25
-1.63 (-22.45%)
since 02/28/25
3-Month
5.62 +0.18%
on 04/01/25
Period Open: 7.68
8.31 -32.25%
on 01/21/25
-2.05 (-26.69%)
since 12/31/24
52-Week
5.62 +0.18%
on 04/01/25
Period Open: 13.34
18.75 -69.97%
on 05/10/24
-7.71 (-57.80%)
since 04/01/24

Most Recent Stories

More News
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025

ITOS : 5.63 (-5.70%)
iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

ITOS : 5.63 (-5.70%)
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones

ITOS : 5.63 (-5.70%)
iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ITOS : 5.63 (-5.70%)
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress

ITOS : 5.63 (-5.70%)
iTeos to Participate in Upcoming Investor Conferences

ITOS : 5.63 (-5.70%)
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates

ITOS : 5.63 (-5.70%)
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress

ITOS : 5.63 (-5.70%)
NCR Atleos Set to Join S&P SmallCap 600

/PRNewswire/ -- NCR Atleos Corp. (NYSE: NATL) will replace iTeos Therapeutics Inc. (NASD: ITOS) in the S&P SmallCap 600 effective prior to the opening of...

SPGI : 510.78 (+0.53%)
ITOS : 5.63 (-5.70%)
NATL : 27.04 (+2.50%)
NCR : 27.08 (+3.24%)
VYX : 9.86 (+1.13%)
New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – June 8, 2023 – USA News Group  â€“  By utilizing newly developed novel mechanisms, biotech researchers and scientists are...

ONCY : 0.5270 (-4.18%)
ONC.TO : 0.77 (-2.53%)
GILD : 111.28 (-0.69%)
ITOS : 5.63 (-5.70%)
GSK : 37.87 (-2.25%)
PGEN : 1.4350 (-3.69%)

Business Summary

iTeos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery and development of immuno-oncology therapeutics. iTeos Therapeutics Inc. is based in Cambridge, United States.

See More

Key Turning Points

3rd Resistance Point 6.21
2nd Resistance Point 6.09
1st Resistance Point 5.86
Last Price 5.63
1st Support Level 5.51
2nd Support Level 5.39
3rd Support Level 5.16

See More

52-Week High 18.75
Fibonacci 61.8% 13.73
Fibonacci 50% 12.18
Fibonacci 38.2% 10.64
Last Price 5.63
52-Week Low 5.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies